These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 1338920

  • 1. [Contribution of a new nitrosourea compound: fotemustine].
    Boaziz C.
    Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
    [Abstract] [Full Text] [Related]

  • 2. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP.
    Cancer Invest; 1994 Dec; 12(4):414-20. PubMed ID: 8032964
    [Abstract] [Full Text] [Related]

  • 3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.
    J Clin Oncol; 2004 Mar 15; 22(6):1118-25. PubMed ID: 15020614
    [Abstract] [Full Text] [Related]

  • 4. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct 15; 38(8):876-80. PubMed ID: 2274396
    [No Abstract] [Full Text] [Related]

  • 5. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P, Dreno B, Bureau B, Litoux P.
    Ann Dermatol Venereol; 1993 Oct 15; 120(6-7):437-40. PubMed ID: 8279787
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Brain metastases of malignant melanomas].
    Boaziz C, Breau JL, Morere JF, Israël L.
    Bull Cancer; 1991 Oct 15; 78(4):347-53. PubMed ID: 1859902
    [Abstract] [Full Text] [Related]

  • 9. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Khayat D, Avril MF, Gerard B, Bertrand P, Bizzari JP, Cour V.
    Melanoma Res; 1992 Sep 15; 2(3):147-51. PubMed ID: 1450667
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
    Siegel R, Hauschild A, Kettelhack C, Kähler KC, Bembenek A, Schlag PM.
    Eur J Surg Oncol; 2007 Jun 15; 33(5):627-32. PubMed ID: 17196362
    [Abstract] [Full Text] [Related]

  • 12. [Malignant melanoma of the uvea].
    Boaziz C, Mazeron JJ, Morere JF, Breau JL, Israël L.
    Bull Cancer; 1993 Jul 15; 80(7):577-83. PubMed ID: 8204938
    [Abstract] [Full Text] [Related]

  • 13. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
    Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB.
    Br J Cancer; 2002 Oct 07; 87(8):840-5. PubMed ID: 12373596
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603).
    Galetta D, Gebbia V, Silvestris N, Ferraù F, Carrozza F, Cigolari S, Russo P, Calista F, Adamo V, Colucci G.
    Lung Cancer; 2011 Apr 07; 72(1):59-63. PubMed ID: 20728237
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
    Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S.
    Melanoma Res; 2008 Jun 07; 18(3):220-4. PubMed ID: 18477897
    [Abstract] [Full Text] [Related]

  • 16. Complete remission seven years after treatment for metastatic malignant melanoma.
    Petit T, Borel C, Rixe O, Avril MF, Monnier A, Giroux B, Weil M, Khayat D.
    Cancer; 1996 Mar 01; 77(5):900-2. PubMed ID: 8608481
    [Abstract] [Full Text] [Related]

  • 17. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S, Shapiro J, Westerman D, Prince HM.
    J Clin Oncol; 2007 Oct 01; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract] [Full Text] [Related]

  • 18. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
    Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.
    Ann Oncol; 2014 Mar 01; 25(3):742-746. PubMed ID: 24510314
    [Abstract] [Full Text] [Related]

  • 19. [New toxicity of fotemustine: diffuse interstitial lung disease].
    Bertrand M, Wémeau-Stervinou L, Gauthier S, Auffret M, Mortier L.
    Ann Dermatol Venereol; 2012 Apr 01; 139(4):277-81. PubMed ID: 22482481
    [Abstract] [Full Text] [Related]

  • 20. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU, Wenzel E, Brassow FW, Berger J, Breitbart EW, Teichmann W.
    Cancer Chemother Pharmacol; 1991 Apr 01; 29(1):85-7. PubMed ID: 1742855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.